A key principle for managing ADC side effects is that the toxicity profile is largely determined by the linker-payload combination, not the antibody's target. For example, drugs with a deruxtecan payload will have similar GI toxicities regardless of the target, allowing clinicians to anticipate AEs across a class.

Despite targeting the same protein (Trope-2), different ADCs like sacituzumab govitecan (SG) and sacituzumab tirumotecan (sac-TMT) exhibit unique toxicity profiles due to their different linker-payloads. Clinicians must be prepared for diarrhea with SG versus oral mucositis with sac-TMT, requiring distinct mitigation strategies for drugs that otherwise seem very similar.

When choosing between sacituzumab govitecan (SG) and datopotamab deruxtecan (Datto-DXd), oncologists prioritize the differing side effect profiles (diarrhea/neutropenia vs. stomatitis/ocular) and administration schedules (weekly infusions vs. every three weeks) to match patient lifestyle and comorbidities, rather than focusing solely on efficacy.

GYN oncology nurses are accustomed to GI and hematologic side effects. With mirvetuximab, they must now manage eye-related issues, requiring patient education on prophylactic eye drops and coordination with ophthalmologists for regular exams.

Though TROP2 antibody-drug conjugates share a mechanism, their adverse event profiles differ significantly. Datopotamab-deruxtecan commonly causes stomatitis, while Sacituzumab govitecan is associated with high rates of neutropenia, necessitating drug-specific management.

When choosing between TROP2-directed ADCs like sacituzumab govitecan and datopotamab deruxtecan, the decision often hinges on side effect profiles and scheduling convenience, not superior efficacy. Datopotamab has more oral/ocular issues but is given every three weeks, while sacituzumab causes more neutropenia and requires visits two out of every three weeks.

Despite both being Trop-2 targeted antibody-drug conjugates, Sacituzumab Govitecan and Datopotomab duroxotein have distinct side effects due to different linkers and payloads. Sacituzumab causes neutropenia and diarrhea, while Datopotomab is linked to stomatitis and ocular issues, requiring unique management strategies.

A key principle for clinicians is that an antibody-drug conjugate's adverse events are primarily dictated by its linker-payload (e.g., deruxtecan, vedotin), not its specific antibody target. This allows for anticipating toxicities like neuropathy or GI issues based on the payload class, creating a predictable framework for management across different ADCs.

Despite being advanced targeted therapies, TROP2-directed ADCs present complex safety profiles. Oncologists must manage classic chemotherapy side effects like nausea and cytopenias alongside unique, serious toxicities including stomatitis, ocular issues, and potentially fatal interstitial lung disease, requiring specialized patient monitoring and counseling.